Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Noninvasive assessment of cancer response to therapy

Abstract

Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: HVGGSSV phage binding to treated tumors.
Figure 2: HVGGSSV peptide differentiates between responding and nonresponding tumors.
Figure 3: Peptide assessment of tumor response to all TKIs.
Figure 4: Peptide binding detects response to therapy in all tumor models.

References

  1. Prenen, H. et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. 12, 2622–2627 (2006).

    CAS  Article  Google Scholar 

  2. Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).

    CAS  Article  Google Scholar 

  3. Motzer, R.J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).

    CAS  Article  Google Scholar 

  4. Motzer, R.J. et al. Sunitinib in patients with metastatic renal cell carcinoma. J. Am. Med. Assoc. 295, 2516–2524 (2006).

    CAS  Article  Google Scholar 

  5. Narula, J. et al. Annexin V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 7, 1347–1352 (2001).

    CAS  Article  Google Scholar 

  6. van de Wiele, C. et al. Quantitative tumor apoptosis imaging using technetium-99m–HYNIC annexin V single photon emission computed tomography. J. Clin. Oncol. 21, 3483–3487 (2003).

    Article  Google Scholar 

  7. Belhocine, T. et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8, 2766–2774 (2002).

    CAS  PubMed  Google Scholar 

  8. Ladner, R.C. Polypeptides from phage display. A superior source of in vivo imaging agents. Q. J. Nucl. Med. 43, 119–124 (1999).

    CAS  PubMed  Google Scholar 

  9. Rusckowski, M. et al. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J. Nucl. Med. 41, 363–374 (2000).

    CAS  PubMed  Google Scholar 

  10. Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121–127 (2002).

    CAS  Article  Google Scholar 

  11. Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364–366 (1996).

    CAS  Article  Google Scholar 

  12. Ruoslahti, E. Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. Trans. 32, 397–402 (2004).

    CAS  Article  Google Scholar 

  13. Scott, J.K. & Smith, G.P. Searching for peptide ligands with an epitope library. Science 249, 386–390 (1990).

    CAS  Article  Google Scholar 

  14. Hallahan, D. et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3, 63–74 (2003).

    CAS  Article  Google Scholar 

  15. Schueneman, A.J. et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63, 4009–4016 (2003).

    CAS  PubMed  Google Scholar 

  16. Han, Z., Xiong, C., Mori, T. & Boyd, M.R. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage–displayed CV-N mutant library. Biochem. Biophys. Res. Commun. 292, 1036–1043 (2002).

    CAS  Article  Google Scholar 

  17. Wrighton, N.C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458–464 (1996).

    CAS  Article  Google Scholar 

  18. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955–3964 (2003).

    CAS  Article  Google Scholar 

  19. Hess-Stumpp, H., Haberey, M. & Thierauch, K.H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. ChemBioChem 6, 550–557 (2005).

    CAS  Article  Google Scholar 

  20. Wood, J.M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor–induced responses and tumor growth after oral administration. Cancer Res. 60, 2178–2189 (2000).

    CAS  PubMed  Google Scholar 

  21. Drevs, J. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor–receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015–4022 (2002).

    CAS  PubMed  Google Scholar 

  22. Yazici, S. et al. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 65, 203–215 (2005).

    CAS  Article  Google Scholar 

  23. Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931–4941 (2004).

    CAS  Article  Google Scholar 

  24. Mendel, D.B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).

    CAS  Google Scholar 

  25. Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116–1119 (2003).

    CAS  Article  Google Scholar 

  26. Hallahan, D.E. & Han, Z. Biopanning for phage-displayed peptides binding in treated tumors. Nat. Protoc. published online, doi:10.1038/nprot.2008.24.

Download references

Acknowledgements

This work was supported by US National Cancer Institute grants R01-CA89674, R01-CA112385 and R01-CA125757 (D.E.H.) and the Ingram Charitable Fund and the Vanderbilt-Ingram Cancer Center. We thank E. Ruoslahti (Burnham Institute) for the gift of T7 phage–based random peptide library and A. Kraker and P. Bailey (Pfizer) for technical assistance with mouse models of cancer.

Author information

Authors and Affiliations

Authors

Contributions

Z.H. and A.F. discovered and prioritized peptides. A.F., R.D. and H.O. performed all mouse imaging. H.W. and L.G. performed cell assays microscopy and histology. D.E.H. is the principle investigator and oversaw all studies.

Corresponding author

Correspondence to Dennis E Hallahan.

Ethics declarations

Competing interests

A patent application to the US Patent Office entitled “Imaging cancer response by use of peptide ligands” is pending.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–3 and Supplementary Methods (PDF 12300 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Han, Z., Fu, A., Wang, H. et al. Noninvasive assessment of cancer response to therapy. Nat Med 14, 343–349 (2008). https://doi.org/10.1038/nm1691

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1691

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing